Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Strategic partner Lyell Immunopharma led a $45m round for Eureka Therapeutics, which will use the money to advance a pipeline that includes a treatment for liver cancer.

Existing backer ShangPharma reinvested in a series B round for the Pfizer-backed macrocyclic peptide drug developer.

Meituan Dianping's budget hotel spinoff has secured an eight-figure dollar sum, in a round co-led by Sofina Group and GGV Capital.

Google unit Gradient Ventures and Square have taken part in a $28m round for Oura, the developer of a wearable sleep tracker.

Huya, NTT Docomo Ventures and Samsung Ventures have provided a $6m extension for the livestreaming monetisation platform's latest round.

The industrial management platform developer, which counts Zhongyeda Group as an early investor, pulled in $14.2m through a round led by Jiafu Asset Management.

Wayra-backed Quit Genius has secured series A funding as it prepares to add alcohol and drug options to its digital smoking and vaping cessation products.

SAP.io and existing investor Nvidia both contributed as the speech recognition technology developer nabbed funding in a series A round.

Axel Johnson investment fund Novax co-led a $15.3m round for Fraunhofer Institute's vegan protein and dairy substitute developer.